A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers

Shock

Volumn 5, Issue 2, 1996, Pages 91-96

  Bauer, Robert J ^a   White, Mark L ^a   Wedel, Nancy ^a   Nelson, Betty J ^a   Friedmann, Nadav ^a,d   Cohen, Albert ^b   Hustinx, Willem N M ^c   Kung, Ada H C ^a  

^a XOMA Corporation   (United States)

^b Peninsular Testing Corporation   (United States)

^c U Gene Research BV   (Netherlands)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN BINDING PROTEINS; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLOOD CHEMICAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MEMBRANE PROTEINS;

EID: 0030077332     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199602000-00002     Document Type: Article

References (17)

1. Bone RC: The pathogenesis of sepsis. Ann Int Med 115:457-469, 1991.
2. Weiss J, Elsbach P, Olsson I, Odeberg H: Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 253:2664-2672, 1978.
3. Gazzano-Santoro H, Parent JB, Grinna L, et al: High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 60:4754-4761, 1992.
4. Gray P W, Flaggs G, Leong SR, et al: Cloning of the cDNA of a human neutrophil bactericidal protein. J Biol Chem 264:9505-9509, 1989.
5. Meszaros K, Parent JB, Gazzano-Santaro H, et al: A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J Leukocyte Biol 54:558-563, 1993.
6. 2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 90:1122-1130, 1992.
7. Ammons WS, Kung AHC: Recombinant amino terminal fragment of bactericidal/permeability-increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 41:176-184, 1993.
8. Kohn FR, Ammons WS, Horwitz A, et al: Protective effect of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in experimental endotoxemia. J Infect Dis 168:1307-1310, 1993.
9. 23 in animals challenged with live bacteria. International Conference on Endotoxins, Amsterdam IV. Amsterdam, The Netherlands, 1993, O.22.
10. White ML, Ma JK, Birr CA, Trown PW, Carroll SF: Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA. J Immunol Methods 167:227-235, 1994.
11. Bickel PJ, Doksum KA: Mathematical Statistics: Basic Ideas and Selected Topics. San Francisco CA: Holden-Day, Inc., 1977.
12. Gibaldi N, Perrier D: Pharmacokinetics, 2nd ed., chap. 2. New York: Marcel Dekker, Inc., 1982.
13. 23 in mice, rats, rabbits, and humans. International Conference on Endotoxins, Amsterdam IV. Amsterdam, The Netherlands, 1993, P.3.
14. Bauer RJ, Gibbons JA, Bell DP, Luo Z-P, Young JD: Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther 258:152-158, 1994.
15. Tanswell P, Heinzel G, Greischel A, Krause J: Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther 255:318-324, 1990.
16. Gibaldi N, Perrier D: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, Inc., 1982, p 215.
17. Tanaka H, Okada Y, Kawagishi M, Tokiwa T: Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat. J Pharmacol Exper Ther 251:1199-1203.